Foralumab

DRUG4 trials

Sponsors

Tiziana Life Sciences LTD

Conditions

COVID-19 Lower Respiratory InfectionCOVID-19 Respiratory InfectionCovid19Crohn's DiseaseNAFLDNASH - Nonalcoholic SteatohepatitisSecondary Progressive Multiple SclerosisT2DM (Type 2 Diabetes Mellitus)

Phase 1

A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease

WithdrawnNCT05028946

Tiziana Life Sciences LTDCrohn's Disease

Start: 2022-05-01End: 2023-11-07Updated: 2022-10-20

Phase 2

Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM

WithdrawnNCT03291249

Tiziana Life Sciences LTDNAFLD, NASH - Nonalcoholic Steatohepatitis, T2DM (Type 2 Diabetes Mellitus)

Start: 2017-12-01End: 2019-06-01Updated: 2019-09-12

In-patient COVID-19 Study of Intranasal Foralumab

WithdrawnNCT04983446

Tiziana Life Sciences LTDCovid19, COVID-19 Lower Respiratory Infection, COVID-19 Respiratory Infection

Start: 2022-04-30End: 2022-12-30Updated: 2022-10-19

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

RecruitingNCT06292923

Tiziana Life Sciences LTDSecondary Progressive Multiple Sclerosis

Start: 2023-11-15End: 2025-11-30Target: 54Updated: 2025-10-15